Changes in HPV Knowledge Among College Women from 2008 to 2015
- 292 Downloads
The human papillomavirus (HPV) can cause anogenital cancers and genital warts; however, it can be prevented through the HPV vaccine, which has been available since 2006. While this vaccine is targeted toward 11-to-12-year-olds, 18-to-26-year-old young adult women are eligible for “catch-up” vaccination. Knowledge of HPV may impact HPV vaccine uptake among this population. The purpose of this study was to assess changes in HPV knowledge and HPV vaccine information sources among young adult college women over a 7-year period. Two independent samples (N = 223 for 2008; N = 323 for 2015) completed a 23-item knowledge scale and survey regarding HPV. Adjusted logistic regression models compared the odds of correctly answering each knowledge item between each time period. The study found that HPV knowledge increased significantly over time (p < 0.01). The participants in 2015 were more likely than the 2008 participants to accurately report that a condom can decrease the chance of HPV transmission; there is a vaccine for women that prevents certain types of HPV; HPV can cause genital warts; HPV can be passed to a newborn at birth; and even if you do not see a wart, you can transmit HPV. Recent participants were also more likely to correctly report only women can get HPV as false. While improvements in HPV knowledge were found over time, misperceptions regarding outcomes associated with HPV persist. In order to promote HPV vaccination among this population, health literacy skills, in addition to knowledge, should be improved.
KeywordsHPV vaccination Knowledge Young adult women
The authors would like to acknowledge the researchers who contributed to the data collection in 2008, specifically, Kay Perrin PhD, Eric Buhi PhD, Stephanie Kolar PhD, Robert McDermott PhD, Natalie Hernandez PhD, and Hollie Fuhrmann.
Compliance with Ethical Standards
Conflict of Interest
Ellen Daley has served on the U.S. Scientific Advisory Board for the HPV Vaccine with Merck Pharmaceuticals. All other authors have no conflict to disclose.
No financial disclosures were reported by the authors of this paper.
- 5.Markowitz LE, Dunne E, Saraiya M, Lawson H, Chesson H, Unger E (2007) Quadrivalent human papillomavirus vaccine. MMWR Morb Mortal Wkly Rep 56(RR-2):1–24Google Scholar
- 6.Reagan-Steiner S, Yankey D, Jeyarajah J, Elam-Evans LD, Singleton JA, Curtis CR et al (2015) National, regional, state, and selected local area vaccination coverage among adolescents aged 13–17 years—United States, 2014. MMWR Morb Mortal Wkly Rep 64(29):784–792CrossRefPubMedPubMedCentralGoogle Scholar
- 10.National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services (2005) Theory at a Glance: A Guide for Health Promotion Practice (2nd Edition). NIH Publication Number 05–3896, Washington, D.C.Google Scholar
- 18.Schmidt S, Parsons HM (2014) Vaccination interest and trends in human papillomavirus vaccine uptake in young adult women aged 18 to 26 years in the United States: an analysis using the 2008–2012 National Health Interview Survey. Am J Public Health 104(5):946–953. doi: 10.2105/ajph.2013.301828 CrossRefPubMedPubMedCentralGoogle Scholar
- 25.Coleman, C., Kurtz-Rossi, S., McKinney, J., Pleasant, A., Rootman, I., & Shohet, L. (2011). The Calgary Charter on health literacy: Rationale and core principles for the development of health literacy curricula. http://www.centreforliteracy.qc.ca/sites/default/files/CFL_Calgary_Charter_2011.pdf. Accessed June 7 2015.